January 3, 2013 at 1:19 pm EDT | by Phil Reese
Price of new once-daily AIDS drug draws criticism
Truvada, Gilead, gay news, Washington Blade

(Photo courtesy of Gilead)

SAN FRANCISCO — Gilead’s new once-daily AIDS drug Stribild provides an attractive option for those with HIV who have never started a meds regiment before, but activists say the $33,000 a year price-tag will make it unattainable for most who need it.

“In the long run, the cost to Gilead to actually produce [Stribild] will be a small fraction of its selling price, which means Gilead can show restraint on…pricing and still make an enormous profit,” AIDS Healthcare Foundation president Michael Weinstein told the Huffington Post, after a massive ACT UP San Francisco demonstration at the drug maker’s headquarters over the price.

Activists are putting pressure not just on Gilead, but on lawmakers to intervene and making HIV drugs more affordable for more people.

 

© Copyright Brown, Naff, Pitts Omnimedia, Inc. 2016. All rights reserved.
Washington Blade Newsletter

Signup!

Get our top stories emailed to you every Thursday and specials offers from our partners.